Literature DB >> 16880170

HIV pharmacology: barriers to the eradication of HIV from the CNS.

Bryan McGee1, Nathalie Smith, Francesca Aweeka.   

Abstract

Total eradication of HIV-1 is not yet achievable, in part because reservoirs of latent HIV-1 can develop within lymphoid tissue, the testes, and the central nervous system (CNS). The presence of HIV-1 in the CNS is clinically significant because of its association with the development of HIV dementia, which occurs in up to one fifth of untreated patients. This review summarizes current theory regarding HIV-1 infection within the CNS, describes physiologic and pharmacologic factors limiting CNS penetration of antiretroviral drugs used to treat HIV-1 infection, and reviews current treatment of CNS HIV-1 infection and HIV encephalopathy.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16880170     DOI： 10.1310/AW2H-TP5C-NP43-K6BY

Source DB:  PubMed          Journal:  HIV Clin Trials        ISSN： 1528-4336


  29 in total

Review 1.  Towards nanomedicines for neuroAIDS.

Authors:  Vidya Sagar; Sudheesh Pilakka-Kanthikeel; Ravi Pottathil; Shailendra K Saxena; Madhavan Nair
Journal:  Rev Med Virol       Date:  2014-01-07       Impact factor: 6.989

2.  Nano-NRTIs: efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity.

Authors:  Serguei V Vinogradov; Larisa Y Poluektova; Edward Makarov; Trevor Gerson; Madapathage T Senanayake
Journal:  Antivir Chem Chemother       Date:  2010-10-28

Review 3.  Antiretroviral therapy in macrophages: implication for HIV eradication.

Authors:  Christina Gavegnano; Raymond F Schinazi
Journal:  Antivir Chem Chemother       Date:  2009-10-19

4.  PPARα and PPARγ protect against HIV-1-induced MMP-9 overexpression via caveolae-associated ERK and Akt signaling.

Authors:  Wen Huang; Ibolya E András; Geun Bae Rha; Bernhard Hennig; Michal Toborek
Journal:  FASEB J       Date:  2011-08-12       Impact factor: 5.191

Review 5.  HIV-associated neurological disorders: a guide to pharmacotherapy.

Authors:  Ik L Tan; Justin C McArthur
Journal:  CNS Drugs       Date:  2012-02-01       Impact factor: 5.749

6.  Altered Oligodendrocyte Maturation and Myelin Maintenance: The Role of Antiretrovirals in HIV-Associated Neurocognitive Disorders.

Authors:  Brigid K Jensen; Hubert Monnerie; Maggie V Mannell; Patrick J Gannon; Cagla Akay Espinoza; Michelle A Erickson; Annadora J Bruce-Keller; Benjamin B Gelman; Lisa A Briand; R Christopher Pierce; Kelly L Jordan-Sciutto; Judith B Grinspan
Journal:  J Neuropathol Exp Neurol       Date:  2015-11       Impact factor: 3.685

7.  Lopinavir protein binding in HIV-1-infected pregnant women.

Authors:  F T Aweeka; A Stek; B M Best; C Hu; D Holland; A Hermes; S K Burchett; J Read; M Mirochnick; E V Capparelli
Journal:  HIV Med       Date:  2009-12-03       Impact factor: 3.180

8.  Endothelial cell suppression of peripheral blood mononuclear cell trafficking in vitro during acute exposure to feline immunodeficiency virus.

Authors:  Lola C Hudson; Mary B Tompkins; Rick B Meeker
Journal:  Cell Tissue Res       Date:  2008-07-30       Impact factor: 5.249

Review 9.  NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS.

Authors:  Alireza Minagar; Deborah Commins; J Steven Alexander; Romy Hoque; Francesco Chiappelli; Elyse J Singer; Behrooz Nikbin; Paul Shapshak
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 10.  Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage.

Authors:  Valentin Le Douce; Georges Herbein; Olivier Rohr; Christian Schwartz
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.